Research ArticleTUMOR IMMUNOLOGY

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

See allHide authors and affiliations

Science Immunology  03 Jan 2020:
Vol. 5, Issue 43, eaay1863
DOI: 10.1126/sciimmunol.aay1863

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A twist in the PD-1 tale

Immunotherapies targeting programmed cell death protein 1 (PD-1) that can reverse T cell exhaustion have revolutionized the treatment of cancer. Here, by generating Pdcd1 floxed mice and conditionally deleting PD-1 in T cells or in myeloid cells, Strauss et al. have uncovered a previously unappreciated role for PD-1 expressed on myeloid cells in dampening antitumor immunity. They found that selective ablation of PD-1 in myeloid cells was just as effective at limiting tumor growth as global deletion of PD-1 and have documented the importance of PD-1 in regulating the development and functions of myeloid cells. Although the study does not question the role of PD-1 in T cell exhaustion, the results call for a rethink of how PD-1–centric therapies work.

View Full Text

Stay Connected to Science Immunology